Loading company…
Nephrosant develops kidney transplant rejection tests, including the QiSant test and a needle-free urine test.
Founded in 2017 by CEO Minnie Sarwal as a kidney health spinout of UC San Francisco, Nephrosant is based in California. It develops QiSant and a needle-free urine test to help detect kidney transplant rejection and inform care after transplantation. In March 2021, it raised USD 16 million in Series A funding led by DaVita Venture Group, with DigitalDx Ventures participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in